Menu
Search
|

Menu

Close
X

ACADIA Pharmaceuticals Inc ACAD.OQ (NASDAQ Stock Exchange Global Select Market)

26.15 USD
-- (--)
As of Jul 18
Previous Close 26.15
Open --
Volume --
3m Avg Volume 431,406
Today’s High --
Today’s Low --
52 Week High 28.67
52 Week Low 12.80
Shares Outstanding (mil) 122.40
Market Capitalization (mil) 4,717.31
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY19
63
FY18
224
FY17
125
FY16
17
EPS (USD)
FY19
-0.592
FY18
-1.936
FY17
-1.807
FY16
-2.335
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
74.89
7.92
Price to Book (MRQ)
vs sector
11.36
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
0.00
14.56
LT Debt to Equity (MRQ)
vs sector
0.00
10.21
Return on Investment (TTM)
vs sector
-74.14
14.49
Return on Equity (TTM)
vs sector
-74.18
15.79

EXECUTIVE LEADERSHIP

Stephen Biggar
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Srdjan Stankovic
President, Since 2018
Salary: $524,785.00
Bonus: --
Stephen Davis
Director and Chief Executive Officer, Since 2019
Salary: $719,833.00
Bonus: --
Elena Ridloff
Executive Vice President, Chief Financial Officer, Since 2019
Salary: --
Bonus: --
Austin Kim
Executive Vice President, General Counsel, and Secretary, Since 2018
Salary: $195,704.00
Bonus: $200,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3611 Valley Centre Dr Ste 300
SAN DIEGO   CA   92130-3331

Phone: +1858.5582871

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

SPONSORED STORIES